Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(50.0%)
Phase 2
1(50.0%)
2Total
Phase 4(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03083197Phase 4Active Not Recruiting

Scrub Typhus Antibiotic Resistance Trial

Role: collaborator

NCT04337450Phase 2Active Not Recruiting

DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old

Role: collaborator

NCT02915861Completed

Eschar Investigations in Scrub Typhus

Role: collaborator

NCT02398162Completed

Scrub Typhus Pediatric Immunology Study

Role: collaborator

NCT01328288Completed

Progress Pediatric Study

Role: collaborator

All 5 trials loaded